© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus–Positive Lymphoproliferative Disorder
Affiliations of authors: Department of Molecular Virology, Immunology, and Medical Genetics (SR, MAC), Medical Scientist Program (SR, BWB, AGF, MAC), Department of Internal Medicine (RAB, SV, DB, JC, KKC, CFE, MRG, MAC), Division of Hematology/Oncology (RAB, JC, CFE, MRG, MAC), Integrated Biomedical Graduate Program (BWB, AGF), College of Pharmacy (Chang-Shi Chen, JJX, KKC, Ching-Shih Chen), Comprehensive Cancer Center (JJX, KKC, CFE, Ching-Shih Chen, MAC), Experimental Therapeutics Program (KKC, MP, MRG), Department of Molecular and Cellular Biochemistry (MP), Division of Epidemiology and Biometrics (AKF), The Ohio State University, Columbus
Correspondence to: Michael A. Caligiuri, MD, A458 Starling Loving Hall, 320 W. 10th Ave., Columbus, OH 43210 (e-mail: caligiuri-1{at}medctr.osu.edu)
Background: Immune-compromised individuals are at increased risk for developing aggressive Epstein-Barr virus (EBV)–associated lymphoproliferative disorders after primary EBV infection or for reactivation of a preexisting latent EBV infection. We evaluated the effect of depsipeptide, a histone deacetylase inhibitor, on EBV-positive lymphoblastoid cell lines (LCLs) and Burkitt lymphoma cell lines in a mouse model and explored its mechanism of action in vitro. Methods: We studied EBV-transformed LCLs, which express a latent III (Lat-III) viral gene profile, as do some EBV-positive lymphoproliferative malignancies, and Burkitt lymphoma cell lines, which express a Lat-I viral gene profile. Cell lines were used to characterize depsipeptide-induced apoptosis, which was evaluated by flow cytometry. Flow cytometry, western blot analyses, and histone deacetylase inhibitors were used to investigate components of prodeath and survival pathways in vitro. We studied depsipeptide’s effects on survival with a mouse xenograft model of EBV-positive human B-cell tumors (groups of 10 mice). All statistical tests were two-sided. Results: Depsipeptide (5 mg/m2 of body surface area) treatment was associated with statistically significantly improved survival of mice carrying Lat-III EBV–positive LCL tumors, compared with that of control-treated mice (day 30: for depsipeptide-treated mice, 90% survival, 95% confidence interval [CI] = 73.2% to 100%; for control-treated mice, 20% survival, 95% CI = 5.79% to 69.1%; P<.001), but it was not associated with survival of mice carrying Lat-I EBV–positive Burkitt lymphoma tumors. Depsipeptide induced apoptosis in 64% of LCLs and in 14% of EBV-positive Burkitt lymphoma cells in vitro. Depsipeptide-treated LCL cultures had two distinct cell populations—one sensitive and one resistant to depsipeptide. Depsipeptide-mediated apoptosis was associated with a 12-fold increased level of active caspase 3, but some apoptosis persisted despite z-VAD-fmk treatment to inhibit caspase activity. Depsipeptide-resistant LCLs expressed higher levels of latent membrane protein 1 (LMP1; P = .017), BCL2 (P = .032), and nuclear factor 
B (NF-B) (P<.001) than depsipeptide-sensitive LCLs; this resistance was circumvented by treatment with PS-1145, an inhibitor of NF-B activation (P<.001). Conclusions: Apoptosis is induced by depsipeptide via caspase-dependent and -independent pathways in Lat-III EBV–positive LCLs and is enhanced by inhibiting NF-B activity. Depsipeptide as a treatment for Lat-III EBV–associated lymphoproliferative disorders should be explored further in clinical trials.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. P. Perrine, O. Hermine, T. Small, F. Suarez, R. O'Reilly, F. Boulad, J. Fingeroth, M. Askin, A. Levy, S. J. Mentzer, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies Blood, March 15, 2007; 109(6): 2571 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Khanbolooki, S. T. Nawrocki, T. Arumugam, R. Andtbacka, M. S. Pino, R. Kurzrock, C. D. Logsdon, J. L. Abbruzzese, and D. J. McConkey Nuclear factor-{kappa}B maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2251 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Imre, V. Gekeler, A. Leja, T. Beckers, and M. Boehm Histone Deacetylase Inhibitors Suppress the Inducibility of Nuclear Factor-{kappa}B by Tumor Necrosis Factor-{alpha} Receptor-1 Down-regulation. Cancer Res., May 15, 2006; 66(10): 5409 - 5418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Skov, M. T. Pedersen, L. Andresen, P. Thor Straten, A. Woetmann, and N. Odum Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3-Dependent Expression of MHC Class I-Related Chain A and B Cancer Res., December 1, 2005; 65(23): 11136 - 11145. [Abstract] [Full Text] [PDF]
|
|